Baird raised the firm’s price target on Edwards Lifesciences to $77 from $75 and keeps an Outperform rating on the shares. The firm said its analyst day marks a shift in longer-term growth guides for the company, with management for the first time committing to a multi-year sales growth and double-digit adjusted EPS growth outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target lowered to $80 from $82 at RBC Capital
- Edwards Lifesciences price target lowered to $80 from $102 at Morgan Stanley
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Boeing upgraded, Shopify downgraded: Wall Street’s top analyst calls
- Edwards downgraded to Underperform from Peer Perform at Wolfe Research
